An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells

Overview

Journal Cancer Biother Radiopharm

Specialties Oncology
Pharmacology
Radiology

Date 2019 Jan 3

PMID 30601063

Citations 16

Authors

Massimo Fantini

Justin M David

Hing C Wong

Christina M Annunziata

Philip M Arlen

Kwong Y Tsang

Affiliations

Soon will be listed here.

Abstract

Background: A major mechanism of action for therapeutic antibodies is antibody-dependent cell-mediated cytotoxicity (ADCC). ALT-803 is an interleukin-15 superagonist complex that enhances ADCC against human carcinoma cells in vitro and exerts an antitumor activity in murine, rat, and human carcinomas in vivo. The authors investigated the ability of ALT-803 to modulate ADCC mediated by the humanized IgG1 monoclonal antibody (mAb) NEO-201 against human carcinoma cells.

Materials And Methods: ALT-803 modulating activity on ADCC mediated by NEO-201 was evaluated on several NEO-201 ligand-expressing human carcinoma cells. Purified human natural killer (NK) cells from multiple healthy donors were treated with ALT-803 before their use as effectors in ADCC assay. Modulation of NK cell phenotype and cytotoxic function by exposure to ALT-803 was evaluated by flow cytometry and gene expression analysis.

Results: ALT-803 significantly enhanced ADCC mediated by NEO-201. ALT-803 also upregulated NK activating receptors, antiapoptotic factors, and factors involved in the NK cytotoxicity, as well as downregulated gene expression of NK inhibiting receptors.

Conclusions: These findings indicate that ALT-803 can enhance ADCC activity mediated by NEO-201, by modulating NK activation and cytotoxicity, suggesting a possible clinical use of ALT-803 in combination with NEO-201 for the treatment of human carcinomas.

Citing Articles

Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach.

Hoke A, Takahashi Y, Padget M, Gomez J, Amit M, Burks J Transl Oncol. 2024; 44:101943.

PMID: 38593586 PMC: 11024348. DOI: 10.1016/j.tranon.2024.101943.

Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.

Fantini M, Arlen P, Tsang K Front Immunol. 2023; 14:1275904.

PMID: 38077389 PMC: 10704476. DOI: 10.3389/fimmu.2023.1275904.

Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure.

Schober R, Brandus B, Laeremans T, Iserentant G, Rolin C, Dessilly G J Transl Med. 2023; 21(1):791.

PMID: 37936122 PMC: 10631209. DOI: 10.1186/s12967-023-04669-4.

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C J Exp Clin Cancer Res. 2023; 42(1):76.

PMID: 36991390 PMC: 10053355. DOI: 10.1186/s13046-023-02649-6.

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201.

Tsang K, Fantini M, Zaki A, Mavroukakis S, Morelli M, Annunziata C Cancers (Basel). 2022; 14(20).

PMID: 36291783 PMC: 9599200. DOI: 10.3390/cancers14204999.

References

Kashii Y, Giorda R, Herberman R, Whiteside T, Vujanovic N . Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 1999; 163(10):5358-66. View

Fehniger T, Caligiuri M . Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1):14-32. DOI: 10.1182/blood.v97.1.14. View

Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S . Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol. 2003; 3(6):336-45. DOI: 10.1111/j.1533-869x.2003.01108.x. View

Dunn G, Old L, Schreiber R . The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. DOI: 10.1146/annurev.immunol.22.012703.104803. View

DallOzzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P . Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004; 64(13):4664-9. DOI: 10.1158/0008-5472.CAN-03-2862. View

Sechler J, Barlic J, Grivel J, Murphy P . IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells. Cell Immunol. 2004; 230(2):99-108. DOI: 10.1016/j.cellimm.2004.10.001. View

Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8):3051-7. DOI: 10.1182/blood-2004-07-2974. View

Cadalbert L, Sloss C, Cameron P, Plevin R . Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase. Cell Signal. 2005; 17(10):1254-64. DOI: 10.1016/j.cellsig.2005.01.003. View

Bratke K, Kuepper M, Bade B, Virchow Jr J, Luttmann W . Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur J Immunol. 2005; 35(9):2608-16. DOI: 10.1002/eji.200526122. View

10.

Zhang X, Wei H, Wang H, Tian Z . Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells. Oncol Rep. 2006; 15(2):485-8. View

11.

Schuster M, Nechansky A, Kircheis R . Cancer immunotherapy. Biotechnol J. 2006; 1(2):138-47. DOI: 10.1002/biot.200500044. View

12.

Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H . Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2006; 120(4):781-7. DOI: 10.1002/ijc.22370. View

13.

Ljunggren H, Malmberg K . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007; 7(5):329-39. DOI: 10.1038/nri2073. View

14.

Lin W, Voskens C, Zhang X, Schindler D, Wood A, Burch E . Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood. 2008; 112(3):699-707. PMC: 2481534. DOI: 10.1182/blood-2007-11-122465. View

15.

Lewin A, Reid L, McMahon M, Stark G, Kerr I . Molecular analysis of a human interferon-inducible gene family. Eur J Biochem. 1991; 199(2):417-23. DOI: 10.1111/j.1432-1033.1991.tb16139.x. View

16.

Levy E, Sycz G, Arriaga J, Barrio M, von Euw E, Morales S . Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun. 2009; 15(2):91-100. DOI: 10.1177/1753425908101404. View

17.

Lopez-Albaitero A, Lee S, Morgan S, Grandis J, Gooding W, Ferrone S . Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009; 58(11):1853-64. PMC: 3426289. DOI: 10.1007/s00262-009-0697-4. View

18.

Odman-Ghazi S, Abraha A, Isom E, Whalen M . Dibutyltin activates MAP kinases in human natural killer cells, in vitro. Cell Biol Toxicol. 2010; 26(5):469-79. PMC: 2892640. DOI: 10.1007/s10565-010-9157-3. View

19.

Sonn C, Yu Y, Hong Y, Shim Y, Bluestone J, Min B . Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells. J Leukoc Biol. 2010; 88(5):955-63. PMC: 6608014. DOI: 10.1189/jlb.0310157. View

20.

Elpek K, Rubinstein M, Bellemare-Pelletier A, Goldrath A, Turley S . Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A. 2010; 107(50):21647-52. PMC: 3003106. DOI: 10.1073/pnas.1012128107. View